Telik (original) (raw)

Telik, Inc. was set up in 1988 and was reverse merged into privately held MabVax in May 2014. The major drug of the company was TELINTRA, an investigational agent that was in development for the treatment of myelodysplastic syndrome (MDS) and idiopathic chronic neutropenia.